Tracers / [188Re]Re-tricarbonyl(cyclopentadienylcarbonate)rhenium

[188Re]Re-tricarbonyl(cyclopentadienylcarbonate)rhenium

Also written as [Re-188]tricarbonyl(cyclopentadienylcarbonate)rhenium

Radionuclide: Re-188 t½ 1020 min
Modality: Therapy
Production route: —
Stage: preclinical
Syntheses indexed: 2

Dosimetry and biodistribution studies Radiochemistry methodology

What it is

Compound class: organorhenium tricarbonylcyclopentadienyl (CpTR) radiolabeling reagent/chelate for antibody fragments and peptides
Target / mechanism: —
Clinical application: —
Theranostic pair: —

Regulatory status

FDA: —
EMA (centralised): —
Other approvals: —
Brand names: —

Clinical use

Typical injected activity: —
Uptake time: —

Reported in the literature. Not a dosing recommendation.

Published syntheses

Module	Cassette	Purification	Yield %	RCP %	Precursor / supplier	Source
—	—	—	—	—	Nepsilon-maleoyl-glycyl-lysine	17226973 2007 Bioconjug Chem
—	—	—	15-20%	—	Hynic conjugated MORF	15208502 2004 Nucl Med Commun

Need this precursor?We can point you to suppliers for [188Re]Re-tricarbonyl(cyclopentadienylcarbonate)rhenium, or handle the enquiry for you.

Get in touch

Notes

Added at stage 21 from therapy-discovered.xlsx (bulk PubMed search by isotope/therapy-type/known-agent, not individually researched yet) -- 2 articles found. Target/mechanism, clinical application, indications, approval and precursor fields still need per-agent research and are intentionally left empty.